Product logins

Find logins to all Clarivate products below.


Coronavirus COVID-19 – Epidemiology – Coronavirus COVID-19 Forecaster

The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global COVID-19 forecasts for up to two years from initial outbreak. Base assumptions used in this model have been tested and developed by DRG’s Epidemiology team using a semi-mechanistic methodology, running thousands of simulations with plausible parameter ranges set out by the current literature and benchmarked using daily reported COVID-19-related mortality data from the European Centre for Disease Prevention and Control (ECDC) using goodness-of-fit analysis.
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0cm;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:ZH-CN;}

Forecasting COVID-19 is challenging for several reasons, including the uncertainty in effect size and duration of local nonpharmaceutical interventions and the timing and efficacy of different treatments entering the market. Therefore, DRG’s COVID19 Epidemiology Forecaster is flexible by design. Each variable used in the model is fully adjustable, and the tool allows the addition of up to five interventions. The COVID-19 Epidemiology Forecaster reports the following metrics in a tabular form, as well as in a variety of data visualization graphics:

  • Total case estimates (everyone infected with the virus, including laboratory-confirmed and -unconfirmed cases).
  • Mortality associated with COVID-19.
  • Adjusted infection fatality rate to allow cross-country comparisons.
  • Incident and cumulative hospitalizations.
  • Incident and cumulative intensive care unit (ICU) admissions.
  • Available in both total and age-stratified formats.

The COVID-19 Epidemiology Forecaster allows users to export diagrams and charts as image files that can easily be incorporated into internal or investor/shareholder material.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…